Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This online program is recorded content from the live session at Oncology Congress Spring 2024 and is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. This activity is supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEUs)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

Recently, progress has been made in understanding the pathogenesis and management of gastric and gastroesophageal junction (GEJ) cancers. Biomarkers that play a role in guiding diagnosis and treatment selection have been incorporated into care, and various targeted therapies and immunotherapies have been shown to improve outcomes in these patients. In this activity, expert faculty will review current and emerging treatments for unresectable locally advanced or metastatic gastric and GEJ cancers and how to integrate them into practice based on the latest clinical evidence. Team-based strategies for monitoring and managing treatment-related adverse events and ways to overcome barriers to care in rural and underserved settings will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on April 13, 2024.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Explain the role of biomarkers in gastric/GEJ cancers to guide diagnosis and treatment decisions
• Describe the mechanism of action of emerging systemic therapies for unresectable locally advanced or metastatic gastric/GEJ cancers
• Evaluate clinical evidence on the safety and efficacy of current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers
• Implement team-based strategies for monitoring and managing adverse events associated with systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers

Faculty

Yelena Y. Janjigian, MD
Professor of Medicine
Weill Cornell Medical College
Chief Attending, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-049-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Yelena Y. Janjigian, MD, has disclosed the following relevant financial relationships: advisory board member/consultant for AbbVie, Inc., AmerisourceBergen (now Cencora, Inc.), AskGene Pharma, Inc., Arcus Biosciences, Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly and Company, Geneos Therapeutics, Inc., GSK, Guardant Health, Inc., Imugene, Inspirna, Merck & Co., Inc., Merck Serono, Mersana Therapeutics, Inc., Pfizer, Inc., Sanofi Genzyme, Seagen, Inc., Silverback Therapeutics (now ARS Pharmaceuticals), and Zymeworks, Inc.; speakers’ bureau for AbbVie, Inc., Amerisource Bergen (now Cencora, Inc.), AskGene Pharma, Inc., Arcus Biosciences, Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Inc., Eisai Co., Ltd., Eli Lilly and Company, Geneos Therapeutics, Inc., GSK, Guardant Health, Inc., Imugene, Inspirna, Lynx Health, Merck & Co., Inc., Merck Serono, Mersana Therapeutics, Inc., Pfizer, Inc., Sanofi Genzyme, Seagen, Inc., Silverback Therapeutics (now ARS Pharmaceuticals), and Zymeworks Inc.; research/grant support from Astellas Pharma, Inc., AstraZeneca Pharmaceuticals, Arcus Biosciences, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc./Roche, Inspirna, Merck & Co., Inc., and Transcenta; stock ownership interest in Inspirna.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.